Legal & General Group
RLMD icon

Legal & General Group’s Relmada Therapeutics RLMD Stock Holding History

Legal & General Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,074
Closed -$6.95K – 3500
2023
Q1 		$6.95K Hold
3,074
– – ﹤0.01% 3260
2022
Q4 		$10.7K Sell
3,074
-5,829
-65% -$51.2K ﹤0.01% 3257
2022
Q3 		$329K Buy
8,903
+1,224
+16% +$33.9K ﹤0.01% 2456
2022
Q2 		$145K Sell
7,679
-122
-2% -$2.66K ﹤0.01% 2750
2022
Q1 		$211K Buy
7,801
+1,033
+15% +$21.4K ﹤0.01% 2649
2021
Q4 		$153K Buy
6,768
+2,377
+54% +$52.9K ﹤0.01% 2807
2021
Q3 		$115K Buy
4,391
+2,231
+103% +$59.7K ﹤0.01% 2814
2021
Q2 		$69K Hold
2,160
– – ﹤0.01% 2854
2021
Q1 		$76K Sell
2,160
-92
-4% -$3.22K ﹤0.01% 2697
2020
Q4 		$72K Hold
2,252
– – ﹤0.01% 2685
2020
Q3 		$84K Sell
2,252
-583
-21% -$22.5K ﹤0.01% 2535
2020
Q2 		$127K Buy
+2,835
New +$120K ﹤0.01% 2469

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Legal & General Group's RLMD Position: Q2 2023 in Review

Legal & General Group sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 3,074 shares — an estimated $6.95K sold.

Legal & General Group first reported a position in RLMD in Q2 2020 and held it in 12 quarters. The position peaked at $329K in Q3 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

  • Legal & General Group reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 3,074 Relmada Therapeutics shares in Q2 2023, an estimated $6.95K.
  • Legal & General Group first reported a position in Relmada Therapeutics in Q2 2020 and held it in 12 quarters.
  • Legal & General Group's Relmada Therapeutics position peaked at $329K in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.